Trial Profile
A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects With Advanced Liver Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 30 Apr 2015 New trial record